Search research articles
Contact Us
Filters
Showing results (1-10 of 27) with videos related to
Page
of 3
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 3, 2007
Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology
Kapila Ratnam, Jennifer A Low
Oncology (Williston Park, N.Y.)
|
April 15, 2005
Clinical trials referral resource. Current clinical trials investigating 3-AP
Jennifer A Low, Mason Schoenfeldt
Current Opinion in Investigational Drugs (London, England : 2000)
|
December 7, 2007
Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer
Cristina Lewis, Jennifer A Low
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 5, 2010
The role of the hedgehog signaling pathway in the development of basal cell carcinoma and opportunities for treatment
Ivor Caro, Jennifer A Low
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 3, 2010
Clinical experience with Hedgehog pathway inhibitors
Jennifer A Low, Frederic J de Sauvage
The Breast Journal
|
March 11, 2004
CA 125 elevation in breast cancer: a case report and review of the literature
Gregory D Leonard, Jennifer A Low, Arlene W Berman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 16, 2004
Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy
Jennifer A Low, Arlene W Berman, Seth M Steinberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 2, 2006
Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone
James J Lee, Jennifer A Low, Earllaine Croarkin, et al.
Cancer Chemotherapy and Pharmacology
|
October 16, 2012
Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential
Patricia M LoRusso, Sarina A Piha-Paul, Monica Mita, et al.
Journal of Cardiovascular Pharmacology
|
October 31, 2012
Daily dosing of vismodegib to steady state does not prolong the QTc interval in healthy volunteers
Richard A Graham, Ilsung Chang, Jin Yan Jin, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 27) with videos related to
Sort By:
Page
of 3
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 3, 2007
Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology
Kapila Ratnam, Jennifer A Low
Oncology (Williston Park, N.Y.)
|
April 15, 2005
Clinical trials referral resource. Current clinical trials investigating 3-AP
Jennifer A Low, Mason Schoenfeldt
Current Opinion in Investigational Drugs (London, England : 2000)
|
December 7, 2007
Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer
Cristina Lewis, Jennifer A Low
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 5, 2010
The role of the hedgehog signaling pathway in the development of basal cell carcinoma and opportunities for treatment
Ivor Caro, Jennifer A Low
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 3, 2010
Clinical experience with Hedgehog pathway inhibitors
Jennifer A Low, Frederic J de Sauvage
The Breast Journal
|
March 11, 2004
CA 125 elevation in breast cancer: a case report and review of the literature
Gregory D Leonard, Jennifer A Low, Arlene W Berman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 16, 2004
Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy
Jennifer A Low, Arlene W Berman, Seth M Steinberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 2, 2006
Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone
James J Lee, Jennifer A Low, Earllaine Croarkin, et al.
Cancer Chemotherapy and Pharmacology
|
October 16, 2012
Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential
Patricia M LoRusso, Sarina A Piha-Paul, Monica Mita, et al.
Journal of Cardiovascular Pharmacology
|
October 31, 2012
Daily dosing of vismodegib to steady state does not prolong the QTc interval in healthy volunteers
Richard A Graham, Ilsung Chang, Jin Yan Jin, et al.
Page
of 3